Scientist, Biomarker

Overview

 

For over 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Scientist, Biomarker

 

We are looking for a team-player scientist with proven track of experience in histology and IHC in preclinical neuroscience to join Charles River Discovery Services site located in Kuopio, Finland.

 

In this position you will be leading projects that focus on identification and assessment of relevant ex vivo endpoints/outcomes of efficacy therapeutic intervention in animal models, including but not limited to, 
multiple sclerosis, neurodegenerative diseases and injury-triggered animal models.
 

You have a strong expertise in various types of ex vivo analysis and interpretation of data derived from preclinical in vivo models. You are strong in techniques and technologies around histology/IHC and image analysis. 
Other expertise in setting up and analysis of other biomolecular technologies, e.g. well plate technologies, gene expression analysis and cell population analysis are considered advantageous.

 

You are able to co-operate, plan, supervise and report ex vivo part of client projects together with our scientific and technical teams. Desired Scientist will be working closely with the core in vivo and imaging teams 
as well as with our clients, through all stages of the research projects. In addition to client projects, scientist will be involved in R&D activities including validations of new markers and assays to support ex vivo outcome 
measurements aspects of various CNS diseases.

 

Qualifications and Experience:
•    Higher education degree in biological science (MSc) with 3+ years of experience, preferably PhD degree
•    Pharmaceutical industry, Preclinical Contract Research Organization or academic post-doctoral experience will be an asset. 
•    Diverse communication skills
•    Scientific expertise with demonstrable understanding of ex vivo neuroscience techniques and neuroimmunology as a component in CNS diseases
•    Hands on experience in development, optimization and validation of immunohistochemistry targets in CNS tissues
•    Experience in other biomolecular techniques like in vitro cell cultures, Luminex, ELISA, gene expression analysis (qPCR, QuantiGene Plex), flow cytometry will be an asset
•    Efficient problem solving skills, ability to coordinate, communicate and prioritize
•    Fluent oral and written scientific English
•    Track record in people management and leadership

 

 

About Discovery

Discovery from Charles River is industry-proven in the successful development of novel therapies, with over 320 patents and 74 preclinical drug candidates delivered to our sponsors in the past 17 years. Backed by more than 650 scientists, our comprehensive, integrated portfolio employs the latest technology and platforms to provide chemistry, biology, and pharmacology services that support clients from the earliest stages of hit identification all the way through to IND. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.

 

About Charles River

Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.  Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.

For more information, please visit www.criver.com.